Ardea Biosciences, Inc. Presents Preliminary Data from a Phase 1 Study of RDEA594 at the 2008 American College of Rheumatology/ARHP Annual Scientific Meeting

SAN DIEGO--(BUSINESS WIRE)--Ardea Biosciences, Inc. (Nasdaq:RDEA) announced today that preliminary data were presented from an ongoing Phase 1 trial of RDEA594, its lead product candidate in development for the treatment of hyperuricemia and gout, at the 2008 American College of Rheumatology (ACR) / Association of Rheumatology Health Professionals (ARHP) Annual Scientific Meeting in San Francisco, California.